Approval Process
Turkish regulations are totally in line with EC Directives (EC 2001/20 and EC 2005/28).
- realistic start-up time: 5.0 months
Recruitment Potential
Cardiovascular diseases are the leading cause of death in Turkey (40% of all deaths). More than 150,000 people died of cardiovascular diseases in 2014. Nearly 150,000 new cancer patients are diagnosed each year. Lung cancer is the most frequent cancer type. The incidence of diabetes in Turkey has doubled over the last 13 years. There were over 7.2 million cases of diabetes in 2014.
People in Turkey are highly motivated to participate in clinical studies. A large percentage of the population is treatment naïve.
Estimated deaths per 100,000 population by cause::
| Diseases | Turkey | World Average | Europe Average |
|---|---|---|---|
| Cardiovascular Diseases | 242.00 | 270.13 | 490.54 |
| Malignant Neoplasms | 91.00 | 112.06 | 208.74 |
| Respiratory Diseases | 43.90 | 36.51 | 39.82 |
| Unintentional Injuries | 22.20 | 24.94 | 20.90 |
| Respiratory Infections | 17.10 | 6.68 | 4.52 |
Data from World Health Organization
Investigators and Sites
There are more than 1,400 hospitals, including 62 University Hospitals with modern and developed technical infrastructure. These institutions have 25 beds per 10,000 population.
Almost one third of the total number of 130,000 doctors are working in the three largest cities: Istanbul, Ankara and Izmir.
Turkish investigators are highly motivated, trained in GCP and experienced in multinational clinical studies.
The number of clinical trials in Turkey has been increasing for the past several years (12% increase between 2013 and 2012). As of June 2015, over 1,900 studies have been conducted in Turkey.